Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
7.36
-0.02 (-0.27%)
May 7, 2026, 4:00 PM EDT - Market closed
Kezar Life Sciences Employees
Kezar Life Sciences had 9 employees as of December 31, 2025. The number of employees decreased by 46 or -83.64% compared to the previous year.
Employees
9
Change (1Y)
-46
Growth (1Y)
-83.64%
Revenue / Employee
n/a
Profits / Employee
-$6,225,889
Market Cap
54.37M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 9 | -46 | -83.64% |
| Dec 31, 2024 | 55 | -3 | -5.17% |
| Dec 31, 2023 | 58 | -26 | -30.95% |
| Dec 31, 2022 | 84 | 28 | 50.00% |
| Dec 31, 2021 | 56 | 9 | 19.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 119 |
| MindWalk Holdings | 102 |
| BeyondSpring | 44 |
| MiNK Therapeutics | 23 |
| iBio, Inc. | 20 |
| Atossa Therapeutics | 16 |
| Instil Bio | 14 |
| Dogwood Therapeutics | 8 |
KZR News
- 5 weeks ago - Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right - Business Wire
- 2 months ago - Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences - Business Wire
- 4 months ago - Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis - Business Wire
- 6 months ago - Kezar Life Sciences Reports Third Quarter 2025 Financial Results - Business Wire
- 6 months ago - Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025 - Business Wire
- 7 months ago - Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives - Business Wire
- 9 months ago - Kezar Life Sciences to Participate in Two Upcoming Investor Conferences - Business Wire
- 9 months ago - Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire